Results 71 to 80 of about 878 (143)

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

International Journal of Cancer, Volume 158, Issue 10, Page 2771-2783, 15 May 2026.
What's New? Circulating nuclear DNA (cir‐nDNA)‐based assessment of minimal residual disease (MRD) offers powerful post‐surgery prognostic insight for stage III colon cancer (CC). Sparse knowledge of post‐surgical variations and origins in cir‐nDNA, however, has limited its clinical application.
Andrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, Alexia Mirandola, Ekaterina Pisareva, Javier Gonzalo Ruiz, Marco Macagno, Nadia Saoudi Gonzalez, Evelyne Crapez, Marc Ychou, Ramon Salazar Soler, Elisabetta Fenocchio, Paula X. Fernandez Calotti, Thibault Mazard, Cristina Santos Vivas, Elena Elez, Federica Di Nicolantonio, Alain R. Thierry   +17 more
wiley   +1 more source

Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 5, May 2026.
This graphical abstract summarizes how classical and emerging histone posttranslational modifications (PTMs), together with their chromatin regulators (writers, erasers, and readers), govern major pathobiological programs in cardiovascular disease.
Yu Zheng, Yu‐Xuan Gao, Mei‐Xing Guo, Li‐Ting Wang, Xiao‐Wen Zheng, Yi‐Hao Liao, Ya Li, Jun‐Ping Zhu, Jia‐Ming Wei   +8 more
wiley   +1 more source

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Whole‐genome sequencing of cell‐free DNA for assessment of minimal residual disease in high‐risk smoldering multiple myeloma

HemaSphere, Volume 10, Issue 4, April 2026.
Abstract In multiple myeloma (MM), minimal residual disease (MRD) is an established endpoint for accelerated drug approval but is limited by a need for serial invasive bone marrow (BM) biopsies, which may under‐sample spatial heterogeneity and result in false negativity.
Chrissy Baker, Elizabeth Hill, Dickran Kazandjian, Marios Papadimitriou, Michael Durante, Abhishek Pandey, Bachisio Ziccheddu, Tomas Jelinek, David Coffey, Brian Walker, Ryan Young, Kylee Maclachlan, Neha Korde, Nickoli Parkinson, Zoe R. Goldstein, Alexi Runnels, William F. Hooper, Dan Landau, Nicolas Robine, Francesco Maura, Ola Landgren, Benjamin Diamond   +21 more
wiley   +1 more source

USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 260-269, April 2026.
We selected breast cancer‐specific DNA methylation markers using The Cancer Genome Atlas (TCGA). We analyzed the methylation and expression patterns of candidate genes in breast cancer cell lines, ctDNA, and tissue samples. The relationship between ctDNA methylation markers and the clinicopathological features of breast cancer patients was investigated.
Young Ju Jeong, Chang‐Ho Jeon, Hoon Kyu Oh, Jeong Kyu Kim, Chun‐Seok Yang, Na‐Rang Lee, Doyeon Kim   +6 more
wiley   +1 more source

Beyond Mutation Detection: Cell-Free DNA for Functional Inference and Adaptive Oncology

DNA
Liquid biopsy has evolved beyond its original role as a minimally invasive approach for mutation detection and is now being developed as a broader analytical framework for cancer detection, stratification, and longitudinal monitoring.
Tetiana Zaichuk
doaj   +1 more source

Cancer treatment monitoring using cell-free DNA fragmentomes

Nature Communications
AbstractCirculating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate ...
Iris van ’t Erve, Bahar Alipanahi, Keith Lumbard, Zachary L. Skidmore, Lorenzo Rinaldi, Laurel K. Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood, Tony Wu, Erica Peters, Karen Bolhuis, Cornelis J. A. Punt, Jennifer Tom, Peter B. Bach, Nicholas C. Dracopoli, Gerrit A. Meijer, Robert B. Scharpf, Victor E. Velculescu, Remond J. A. Fijneman, Alessandro Leal   +21 more
openaire   +5 more sources

Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients

Advanced Science, Volume 13, Issue 13, 3 March 2026.
Mature red blood cells (RBCs) can capture extracellular DNA, with short fragments homologous to cfDNA. This uptake is mediated by apoptotic bodies, which induce RBC oxidative stress, deformation, and accelerated in vivo clearance. The rbcDNA abundance correlates with tumor burden and therapeutic response, highlighting its potential as a liquid biopsy ...
Zihang Zeng, Zongbi Yi, Jing Hu, Jiali Li, Yu Xu, Xiuli Guo, Qian Ji, Kaixiang Feng, Ying Zhang, Sirui Bai, Yushuang Tan, Yufei Yan, Linzhi Han, Jing Jiang, Tengfei Wang, Xiang Wang, Ziqing Zhan, Ruiying Huang, Jinfang Zhang, Conghua Xie, Binghe Xu   +20 more
wiley   +1 more source

Cell-Free Mitochondrial DNA in Cell Culture Supernatant: Fragment Size Analysis and FBS Contamination Assessment

DNA
Background/Objectives: Circulating cell-free DNA (cfDNA) consists of genomic DNA (cf-nDNA) and mitochondrial DNA (cf-mtDNA) fragments released from cells primarily through apoptosis and necrosis.
Patrizia Cesare, Sabrina Colafarina, Antonella Bonfigli, Anna Rita Volpe, Massimo Aloisi, Osvaldo Zarivi, Anna Maria Giuseppina Poma   +6 more
doaj   +1 more source

Lymph‐based liquid biopsy: Current progress and future potential

Interdisciplinary Medicine, Volume 4, Issue 2, March 2026.
Recent evidence under the revised Starling principle indicates that lymph‐based liquid biopsies may offer superior diagnostic performance over blood‐based counterparts in certain clinical scenarios, such as early‐stage solid tumor detection. Currently, various biomarkers within the lymphatic system show significant diagnostic potential for a range of ...
Dongdong Liu, Leheng Cheng, Xiaolin Hu, Sergio Bernardini, Hong Zhang, Ling Zhu, Yang Luo   +6 more
wiley   +1 more source